(-0.58%) 5 022.21 points
(-0.12%) 37 753 points
(-1.15%) 15 683 points
(0.12%) $82.79
(1.87%) $1.744
(-0.14%) $2 385.00
(-0.02%) $28.40
(-0.51%) $949.30
(-0.02%) $0.937
(-0.05%) $10.99
(-0.07%) $0.802
(0.00%) $94.06
Live Chart Being Loaded With Signals
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries...
Stats | |
---|---|
Today's Volume | 6.42M |
Average Volume | 0.00 |
Market Cap | 2.46B |
EPS | HKD0 ( 2024-03-29 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -3.14 |
ATR14 | HKD0.268 (4.77%) |
Volume Correlation
Venus MedTech HangZhou Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Venus MedTech HangZhou Correlation - Currency/Commodity
Venus MedTech HangZhou Financials
Annual | 2022 |
Revenue: | HKD406.46M |
Gross Profit: | HKD314.00M (77.25 %) |
EPS: | HKD-2.56 |
Q2 | 2023 |
Revenue: | HKD127.81M |
Gross Profit: | HKD100.62M (78.73 %) |
EPS: | HKD-0.400 |
Q1 | 2023 |
Revenue: | HKD127.81M |
Gross Profit: | HKD100.62M (78.73 %) |
EPS: | HKD-0.400 |
Q4 | 2022 |
Revenue: | HKD98.25M |
Gross Profit: | HKD74.91M (76.25 %) |
EPS: | HKD-0.980 |
Financial Reports:
No articles found.
Venus MedTech HangZhou
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators